These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30853469)

  • 1. Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate.
    Watanabe K; Oda S; Matsubara A; Akai S; Yokoi T
    Toxicol Lett; 2019 Jun; 307():49-58. PubMed ID: 30853469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin.
    Matsubara A; Oda S; Akai S; Tsuneyama K; Yokoi T
    Toxicol Lett; 2018 Jul; 291():184-193. PubMed ID: 29679711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy.
    Marais GE; Larson KK
    Ann Intern Med; 1990 Feb; 112(3):228-30. PubMed ID: 2297197
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin-fibrate combination therapy.
    Shek A; Ferrill MJ
    Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
    Jones PH; Davidson MH
    Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of atorvastatin and gemfibrozil plus physical activity: an animal model of statin/fibrate-induced myopathy.
    Zabihi M; Askarian F; Hekmatimoghaddam S; Zabihi MS; Vahidi F
    Somatosens Mot Res; 2021 Mar; 38(1):90-94. PubMed ID: 33263458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.
    Unal A; Torun E; Sipahioglu MH; Tokgoz B; Kaya MG; Oymak O; Utas C
    Intern Med; 2008; 47(11):1017-9. PubMed ID: 18520113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute kidney injury model established by systemic glutathione depletion in mice.
    Matsubara A; Oda S; Jia R; Yokoi T
    J Appl Toxicol; 2019 Jun; 39(6):919-930. PubMed ID: 30768730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
    Oldemeyer JB; Lund RJ; Koch M; Meares AJ; Dunlay R
    Cardiology; 2000; 94(2):127-8. PubMed ID: 11173785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
    Pierce LR; Wysowski DK; Gross TP
    JAMA; 1990 Jul; 264(1):71-5. PubMed ID: 2355431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin-associated myopathy.
    Thompson PD; Clarkson P; Karas RH
    JAMA; 2003 Apr; 289(13):1681-90. PubMed ID: 12672737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
    Alford JC; Saseen JJ; Allen RR; Nair KV
    Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics.
    Landesman KA; Stozek M; Freeman NJ
    Conn Med; 1999 Aug; 63(8):455-7. PubMed ID: 10500341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed presentation of severe rhabdomyolysis leading to acute kidney injury following atorvastatin-gemfibrozil combination therapy: a case report.
    Dalugama C; Pathirage M; Kularatne SAM
    J Med Case Rep; 2018 May; 12(1):143. PubMed ID: 29784023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of a Skeletal Muscle Injury and Drug Interactions in Lovastatin- and Fenofibrate-Coadministered Dogs.
    Kawata R; Yokoi T
    Int J Toxicol; 2019; 38(3):192-201. PubMed ID: 31113311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.